These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 12549960)

  • 1. Association of HMG-CoA reductase inhibitors with neuropathy.
    Backes JM; Howard PA
    Ann Pharmacother; 2003 Feb; 37(2):274-8. PubMed ID: 12549960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statin-associated peripheral neuropathy: review of the literature.
    Chong PH; Boskovich A; Stevkovic N; Bartt RE
    Pharmacotherapy; 2004 Sep; 24(9):1194-203. PubMed ID: 15460180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HMG-CoA-reductase inhibitors and neuropathy: reports to the Netherlands Pharmacovigilance Centre.
    de Langen JJ; van Puijenbroek EP
    Neth J Med; 2006 Oct; 64(9):334-8. PubMed ID: 17057271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statin-associated incident diabetes: a literature review.
    Park ZH; Juska A; Dyakov D; Patel RV
    Consult Pharm; 2014; 29(5):317-34. PubMed ID: 24849689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of statin use with peripheral neuropathy in the U.S. population 40 years of age or older.
    Tierney EF; Thurman DJ; Beckles GL; Cadwell BL
    J Diabetes; 2013 Jun; 5(2):207-15. PubMed ID: 23121724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rhabdomyolysis and HMG-CoA reductase inhibitors.
    Omar MA; Wilson JP; Cox TS
    Ann Pharmacother; 2001 Sep; 35(9):1096-107. PubMed ID: 11573861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid lowering drugs prescription and the risk of peripheral neuropathy: an exploratory case-control study using automated databases.
    Corrao G; Zambon A; Bertù L; Botteri E; Leoni O; Contiero P
    J Epidemiol Community Health; 2004 Dec; 58(12):1047-51. PubMed ID: 15547071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statins an oft-prescribed drug is implicated in peripheral neuropathy: The time to know more.
    Al-Kuraishy HM; Al-Gareeb AI; Hussien NR; Al-Naimi MS; Rasheed HA
    J Pak Med Assoc; 2019 Aug; 69(Suppl 3)(8):S108-S112. PubMed ID: 31603889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statin neuropathy?
    Coulson WF
    J Fam Pract; 2011 Apr; 60(4):182-4. PubMed ID: 21472148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydroxymethylglutaryl-coenzyme A reductase inhibitors in osteoporosis management.
    Coons JC
    Ann Pharmacother; 2002 Feb; 36(2):326-30. PubMed ID: 11847956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral polyneuropathy in patients receiving long-term statin therapy.
    Özdemir IH; Copkiran Ö; Tıkız H; Tıkız C
    Turk Kardiyol Dern Ars; 2019 Oct; 47(7):554-563. PubMed ID: 31582682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peripheral neuropathy and statins.
    Prescrire Int; 2007 Dec; 16(92):247-8. PubMed ID: 18092417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in understanding drug-induced neuropathies.
    Peltier AC; Russell JW
    Drug Saf; 2006; 29(1):23-30. PubMed ID: 16454532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statin-fibrate combination therapy.
    Shek A; Ferrill MJ
    Ann Pharmacother; 2001; 35(7-8):908-17. PubMed ID: 11485144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The potential role of HMG-CoA reductase inhibitors in pediatric nephrotic syndrome.
    Prescott WA; Streetman DA; Streetman DS
    Ann Pharmacother; 2004 Dec; 38(12):2105-14. PubMed ID: 15507504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peripheral neuropathy due to statins.
    Prescrire Int; 2000 Aug; 9(48):115. PubMed ID: 11067722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with statins and peripheral neuropathy: results of 36-months a prospective clinical and neurophysiological follow-up.
    Otruba P; Kanovsky P; Hlustik P
    Neuro Endocrinol Lett; 2011; 32(5):688-90. PubMed ID: 22167150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is statin-associated cognitive impairment clinically relevant? A narrative review and clinical recommendations.
    Rojas-Fernandez CH; Cameron JC
    Ann Pharmacother; 2012 Apr; 46(4):549-57. PubMed ID: 22474137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3-hydroxyl-3-methylglutaryl coenzyme A reductase inhibitor use in chronic liver disease: a therapeutic controversy.
    Tzefos M; Olin JL
    J Clin Lipidol; 2011; 5(6):450-9. PubMed ID: 22108148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diplopia, blepharoptosis, and ophthalmoplegia and 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor use.
    Fraunfelder FW; Richards AB
    Ophthalmology; 2008 Dec; 115(12):2282-5. PubMed ID: 18930555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.